USPTO Patent Grant for CAH Treatment Compound

ChangeBridge: Patent Grants - Therapeutics (A61P)

Published March 24th, 2026

Detected March 24th, 2026

Summary

The USPTO has granted patent US12582634B2 to Neurocrine Biosciences, Inc. for a compound and synthetic methods for treating congenital adrenal hyperplasia (CAH). The patent covers specific chemical structures and their preparation, aiming to provide new therapeutic options for this condition.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has issued patent US12582634B2, granting Neurocrine Biosciences, Inc. exclusive rights to a specific compound and its synthetic methods for treating congenital adrenal hyperplasia (CAH). The patent details the chemical structure of the compound, identified as 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, along with its pharmaceutically acceptable salts and crystalline forms.

This patent grant signifies a new intellectual property asset for Neurocrine Biosciences, potentially impacting future drug development and market exclusivity in the therapeutic area of CAH. While this is a patent grant and not a regulatory rule with compliance deadlines, it is relevant for pharmaceutical companies operating in the endocrinology and rare disease space. Compliance officers should note this as a development in the competitive landscape for CAH treatments.

Source document (simplified)

← USPTO Patent Grants

Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine

Grant US12582634B2 Kind: B2 Mar 24, 2026

Assignee

Neurocrine Biosciences, Inc.

Inventors

Andrew Becker, Scott Stirn, Joel Radisson, Christina Marie Costa

Abstract

The present disclosure relates to the fields of chemistry and medicine, more particularly to processes for making 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine (Compound 1), pharmaceutically acceptable salts, and crystalline forms thereof, for the treatment of congenital adrenal hyperplasia (CAH).

CPC Classifications

A61K 31/426 A61K 9/0095 A61K 9/107 A61K 9/28 A61K 9/4833 A61K 45/06 A61K 47/10 A61K 47/14 A61K 47/22 A61K 47/26 A61K 47/32 A61K 31/573 A61K 2300/00 A61K 9/0053 A61K 9/1635 A61K 9/1652 C07D 277/42 C07B 2200/13 A61P 5/00 C07C 209/52 C07C 249/02 C07C 259/06 C07C 211/29 C07C 251/24 G01N 33/74